Source:http://linkedlifedata.com/resource/pubmed/id/10404320
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1999-9-30
|
pubmed:abstractText |
Trovafloxacin is a potentially useful agent for treatment of infections caused by cephalosporin-resistant Streptococcus pneumoniae. We studied the effectiveness of trovafloxacin therapy and examined the correlation between pharmacodynamic indices in serum and lung, and bacterial killing. Immunocompetent Balb/c mice were infected by intranasal inoculation of a cephalosporin-resistant S. pneumoniae isolate (MIC of ceftriaxone and trovafloxacin 2 and 0.06 mg/L, respectively). Trovafloxacin 10-30 mg/kg/day in one or three divided doses was started 15 h after infection. Serum and lung drug concentrations were measured at multiple time points for 24 h. Serum concentrations peaked at 30-60 min and lung concentrations approximately 30 min later. The serum T1/2 was approximately 9 h and lung T1/2 varied from 5 to 9 h. Lung AUC and Cmax values were 2-3 times greater than those in serum. At the start of therapy lung bacterial concentrations were 8.4 +/- 0.3 log10 cfu/mL and 24 h later had decreased by 3.5 +/- 0.2, 4.0 +/- 0.2, 0.8 +/- 0.3 and 1.0 +/- 1.2 log10 cfu/mL with 30 mg/kg x 1, 10 mg/kg x 3, 10 mg/kg x 1 and 3.3 mg/kg x 3 regimens, respectively. Although the larger dosages were more effective (P < 0.001) the differences between divided and single dosage regimens were not significant. Trovafloxacin serum AUC/MIC ratio correlated best with bacterial killing in the lungs over 24 h. Trovafloxacin is likely to be useful in the treatment of cephalosporin-resistant S. pneumoniae pneumonia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cephalosporins,
http://linkedlifedata.com/resource/pubmed/chemical/Fluoroquinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Naphthyridines,
http://linkedlifedata.com/resource/pubmed/chemical/trovafloxacin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0305-7453
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
811-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10404320-Analysis of Variance,
pubmed-meshheading:10404320-Animals,
pubmed-meshheading:10404320-Anti-Infective Agents,
pubmed-meshheading:10404320-Cephalosporin Resistance,
pubmed-meshheading:10404320-Cephalosporins,
pubmed-meshheading:10404320-Disease Models, Animal,
pubmed-meshheading:10404320-Female,
pubmed-meshheading:10404320-Fluoroquinolones,
pubmed-meshheading:10404320-Lung,
pubmed-meshheading:10404320-Mice,
pubmed-meshheading:10404320-Mice, Inbred BALB C,
pubmed-meshheading:10404320-Microbial Sensitivity Tests,
pubmed-meshheading:10404320-Naphthyridines,
pubmed-meshheading:10404320-Pneumonia, Pneumococcal,
pubmed-meshheading:10404320-Streptococcus pneumoniae
|
pubmed:year |
1999
|
pubmed:articleTitle |
Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
|
pubmed:affiliation |
University of Texas Southwestern Medical Center, Dallas 75235, USA.
|
pubmed:publicationType |
Journal Article
|